<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093015</url>
  </required_header>
  <id_info>
    <org_study_id>20010184</org_study_id>
    <secondary_id>TREAT</secondary_id>
    <nct_id>NCT00093015</nct_id>
  </id_info>
  <brief_title>Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)</brief_title>
  <official_title>Trial to Reduce Cardiovascular Events With Aranesp® Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of treatment of anemia with darbepoetin
      alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular
      events, and (2) progression to end-stage renal disease or death, in subjects with chronic
      kidney disease and type 2 diabetes mellitus.

      Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to the first confirmed composite event. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to All-cause Mortality or End Stage Renal Disease (ESRD)</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to first event of all-cause mortality or ESRD. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to All-cause Mortality</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to all-cause mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cardiovascular Mortality</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to cardiovascular (CV) mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Myocardial Infarction</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to fatal or non-fatal myocardial infarction (MI). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cerebrovascular Accident</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to fatal or non-fatal cerebrovascular accident (CVA). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Congestive Heart Failure</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to fatal or non-fatal congestive heart failure(CHF). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to End Stage Renal Disease</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to end stage renal disease (ESRD). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>GFR was estimated using the following MDRD formula: 186 x [Serum creatinine]^(-1.154) x [Age]^(-0.203) x [0.742 if subject is female] x [1.210 if subject is black]. Change from baseline in eGFR at week 49 for each treatment group are presented. The treatment effect of the rate of decline in eGFR per year was estimated using the mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Fatigue Relative to Baseline at Week 25</measure>
    <time_frame>Baseline and week 25</time_frame>
    <description>Change in patient reported fatigue measured by the Functional Assessment of Cancer Therapy (FACT) - Fatigue scale from baseline to week 25. Range and direction of scale: 0 = most fatigue; 52 = least fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization Due to Acute Myocardial Ischemia</measure>
    <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
    <description>Time from randomization to hospitalization due to acute myocardial ischemia. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4038</enrollment>
  <condition>Kidney Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume and dose frequency changes resembling dosing in the active treatment group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemoglobin less than or equal to 11 g/dL

          -  History of Chronic Kidney Disease

          -  eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2
             and less than or equal to 60 mL/min/1.73 m2

          -  Tsat (transferrin saturation) greater than 15%

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Erythropoietic protein use within 12 weeks of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC, Locatelli F, Parfrey PS; TREAT Investigators. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011 Apr;6(4):845-55. doi: 10.2215/CJN.06450710. Epub 2011 Jan 6.</citation>
    <PMID>21212421</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J. 2011 Oct;162(4):748-755.e3. doi: 10.1016/j.ahj.2011.07.016.</citation>
    <PMID>21982669</PMID>
  </reference>
  <reference>
    <citation>Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar;149(3):408-13. Erratum in: Am Heart J. 2005 Jul;150(1):53.</citation>
    <PMID>15864229</PMID>
  </reference>
  <reference>
    <citation>Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.</citation>
    <PMID>19880844</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109.</citation>
    <PMID>20843249</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2004</study_first_submitted>
  <study_first_submitted_qc>September 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2004</study_first_posted>
  <results_first_submitted>August 6, 2010</results_first_submitted>
  <results_first_submitted_qc>August 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2010</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 25 Aug 2004 Last Subject Enrolled: 04 Dec 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
        </group>
        <group group_id="P2">
          <title>Darbepoetin Alfa</title>
          <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2026"/>
                <participants group_id="P2" count="2012"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="2019"/>
                <participants group_id="P2" count="2004"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1361"/>
                <participants group_id="P2" count="1348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="665"/>
                <participants group_id="P2" count="664"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="385"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Darbepoetin Alfa</title>
          <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2012"/>
            <count group_id="B2" value="2026"/>
            <count group_id="B3" value="4038"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="10.7"/>
                    <measurement group_id="B2" value="67.5" spread="10.6"/>
                    <measurement group_id="B3" value="67.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1178"/>
                    <measurement group_id="B2" value="1134"/>
                    <measurement group_id="B3" value="2312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="834"/>
                    <measurement group_id="B2" value="892"/>
                    <measurement group_id="B3" value="1726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1270"/>
                    <measurement group_id="B2" value="1300"/>
                    <measurement group_id="B3" value="2570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="414"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborigine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of cardiovascular disease</title>
          <description>Cardiovascular disease history is based on the cardiovascular medical history case report form.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With history of cardiovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1287"/>
                    <measurement group_id="B2" value="1355"/>
                    <measurement group_id="B3" value="2642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without history of cardiovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="725"/>
                    <measurement group_id="B2" value="671"/>
                    <measurement group_id="B3" value="1396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline proteinuria level</title>
          <description>Baseline proteinuria level (g/g creat). Baseline proteinuria is defined as the last non-missing measurement prior or on the day of first investigational product.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 1 g/g creat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="686"/>
                    <measurement group_id="B2" value="711"/>
                    <measurement group_id="B3" value="1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 1 g/g creat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1324"/>
                    <measurement group_id="B2" value="1315"/>
                    <measurement group_id="B3" value="2639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)</title>
        <description>Time from randomization to the first confirmed composite event. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)</title>
          <description>Time from randomization to the first confirmed composite event. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="602"/>
                    <measurement group_id="O2" value="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented. The primary cardiovascular composite endpoint was tested at the 0.04056 significance level at final analysis after accounting for 4 planned interim analyses (overall alpha = 0.048).</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to All-cause Mortality or End Stage Renal Disease (ESRD)</title>
        <description>Time from randomization to first event of all-cause mortality or ESRD. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Mortality or End Stage Renal Disease (ESRD)</title>
          <description>Time from randomization to first event of all-cause mortality or ESRD. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="618"/>
                    <measurement group_id="O2" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented. The primary renal composite endpoint was tested at the 0.002 significance level at final analysis.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to All-cause Mortality</title>
        <description>Time from randomization to all-cause mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Mortality</title>
          <description>Time from randomization to all-cause mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cardiovascular Mortality</title>
        <description>Time from randomization to cardiovascular (CV) mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cardiovascular Mortality</title>
          <description>Time from randomization to cardiovascular (CV) mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Myocardial Infarction</title>
        <description>Time from randomization to fatal or non-fatal myocardial infarction (MI). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Myocardial Infarction</title>
          <description>Time from randomization to fatal or non-fatal myocardial infarction (MI). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cerebrovascular Accident</title>
        <description>Time from randomization to fatal or non-fatal cerebrovascular accident (CVA). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cerebrovascular Accident</title>
          <description>Time from randomization to fatal or non-fatal cerebrovascular accident (CVA). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Congestive Heart Failure</title>
        <description>Time from randomization to fatal or non-fatal congestive heart failure(CHF). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Congestive Heart Failure</title>
          <description>Time from randomization to fatal or non-fatal congestive heart failure(CHF). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to End Stage Renal Disease</title>
        <description>Time from randomization to end stage renal disease (ESRD). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to End Stage Renal Disease</title>
          <description>Time from randomization to end stage renal disease (ESRD). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline</title>
        <description>GFR was estimated using the following MDRD formula: 186 x [Serum creatinine]^(-1.154) x [Age]^(-0.203) x [0.742 if subject is female] x [1.210 if subject is black]. Change from baseline in eGFR at week 49 for each treatment group are presented. The treatment effect of the rate of decline in eGFR per year was estimated using the mixed model.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>Subjects were analyzed as randomized using all available eGFR measurements, except eGFR measurements measured after subjects develop ESRD since creatinine measurements were no longer reliable or meaningful for eGFR calculation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline</title>
          <description>GFR was estimated using the following MDRD formula: 186 x [Serum creatinine]^(-1.154) x [Age]^(-0.203) x [0.742 if subject is female] x [1.210 if subject is black]. Change from baseline in eGFR at week 49 for each treatment group are presented. The treatment effect of the rate of decline in eGFR per year was estimated using the mixed model.</description>
          <population>Subjects were analyzed as randomized using all available eGFR measurements, except eGFR measurements measured after subjects develop ESRD since creatinine measurements were no longer reliable or meaningful for eGFR calculation.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="10.60"/>
                    <measurement group_id="O2" value="-1.30" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>Nominal p-value is from the term treatment group*visit in the mixed model.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline eGFR and the stratification factors of proteinuria and CVD history.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
            <estimate_desc>Estimated difference in rate of decline in eGFR per year between darbepoetin alfa and placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Reported Fatigue Relative to Baseline at Week 25</title>
        <description>Change in patient reported fatigue measured by the Functional Assessment of Cancer Therapy (FACT) – Fatigue scale from baseline to week 25. Range and direction of scale: 0 = most fatigue; 52 = least fatigue</description>
        <time_frame>Baseline and week 25</time_frame>
        <population>Subjects with both the baseline and at least post-baseline measurement at week 25 for FACT-fatigue were included in the analysis and were analyzed as randomized. Last observation carried forward (LOCF) using last non-missing post-baseline value was used for missing post-baseline data for subjects who were still on study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Reported Fatigue Relative to Baseline at Week 25</title>
          <description>Change in patient reported fatigue measured by the Functional Assessment of Cancer Therapy (FACT) – Fatigue scale from baseline to week 25. Range and direction of scale: 0 = most fatigue; 52 = least fatigue</description>
          <population>Subjects with both the baseline and at least post-baseline measurement at week 25 for FACT-fatigue were included in the analysis and were analyzed as randomized. Last observation carried forward (LOCF) using last non-missing post-baseline value was used for missing post-baseline data for subjects who were still on study.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1769"/>
                <count group_id="O2" value="1762"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="10.3"/>
                    <measurement group_id="O2" value="4.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value is presented.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
            <estimate_desc>Difference (darbepoetin alfa - placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospitalization Due to Acute Myocardial Ischemia</title>
        <description>Time from randomization to hospitalization due to acute myocardial ischemia. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
        <time_frame>Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first</time_frame>
        <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was &lt;9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa</title>
            <description>Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospitalization Due to Acute Myocardial Ischemia</title>
          <description>Time from randomization to hospitalization due to acute myocardial ischemia. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.</description>
          <population>The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
                <count group_id="O2" value="2012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>Nominal p-value from a 2-sided log rank test is presented.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A 2-sided log-rank test comparing the survival functions of the 2 groups stratified by baseline proteinuria and CV disease (CVD) history.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Treatment effect was estimated using a hazards ratio and 95% confidence interval (CI) obtained from a Cox proportional hazards model stratified by baseline proteinuria and CVD history. Hazard ratio (darbepoetin alfa / placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Differential follow-up up to 4.6 years</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Darbepoetin Alfa</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1219" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1235" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AV dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac valve sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac valve vegetation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Microvascular angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pacemaker generated arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypospadias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urachal abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haematotympanum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Otosalpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retinopathy proliferative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bezoar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colonic atony</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Corynebacterium infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Creutzfeldt-Jakob disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Embolic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Emphysematous cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Infected bunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intraspinal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyelonephritis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subacute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Uterine abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dialysis device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Eyeball rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Heart injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intervertebral disc injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intraocular lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pacemaker complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Methicillin-resistant staphylococcal aureus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acidosis hyperchloraemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Enzyme abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Endometrial cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lentigo maligna stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Paget's disease of the breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Leukoaraiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Impaired self-care</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atonic urinary bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranoproliferative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Kidney enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Mesangioproliferative glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal papillary necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Laryngeal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Wegener's granulomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin graft failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal cavity drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Removal of inert matter from skin or subcutaneous tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Aorto-duodenal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diabetic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1547" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="1571" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="279" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="351" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="322" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="417" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="414" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="249" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="307" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="301" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="332" subjects_at_risk="2004"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="2019"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="2004"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>4047 subjects were enrolled, but before unblinding, all information from 9 subjects was excluded from two sites (3 and 6 subjects, respectively) that did not adhere to Good Clinical Practice guidelines. 4038 subjects were analyzed and reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

